Brussels - Delayed Quote EUR

Ion Beam Applications SA (IBAB.BR)

Compare
12.74
-0.12
(-0.93%)
At close: January 17 at 5:35:27 PM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Pierre Mottet Chairman of The Board 61.5k -- 1962
Mr. Olivier Legrain CEO, MD & Executive Director 815.89k -- 1968
Mr. Yves Jongen Founder, Chief Research Officer, MD & Executive Director 564.08k -- 1947
Ms. Soumya Chandramouli Chief Financial Officer -- -- 1977
Marc Van der Burght Chief Operation Officer -- -- --
Olivier Lechien Corporate Communication Director -- -- --
Thomas Canon Sustainability Program Director -- -- --
Mr. Henri de Romree Deputy CEO -- -- --
Bruno Scutnaire President of IBA RadioPharma Solutions -- -- --

Ion Beam Applications SA

3, Chemin du Cyclotron
Louvain-la-Neuve, 1348
Belgium
32 1 047 58 11 https://www.iba-worldwide.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
1,943

Description

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Corporate Governance

Ion Beam Applications SA’s ISS Governance QualityScore as of January 1, 2025 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 10; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 20, 2025 at 6:00 AM UTC

Ion Beam Applications SA Earnings Date

Recent Events

June 27, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers